pimobendan has been researched along with Cardiac Diseases in 10 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described." | 5.27 | Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Schummer, C; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2018) |
| "Pimobendan is a drug with both inotropic and vasodilatory properties and is widely used for the treatment of heart failure in dogs." | 2.46 | Current use of pimobendan in canine patients with heart disease. ( Boswood, A, 2010) |
| " Angiotensin-converting enzyme inhibitor dosage and RAAS inhibition were greater in stage D, compared to stage C dogs." | 1.56 | Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease. ( Adin, D; Atkins, C; Kurtz, K; Papich, MG; Vaden, S, 2020) |
| " Consequently, with respect to the pharmacological effects and the adverse events, the racemate is equivalent to the eutomer." | 1.30 | Comparative cardiac toxicity of the i.v. administered benzimidazole pyridazinon derivative Pimobendan and its enantiomers in female Beagle dogs. ( Eckenfels, A; Güttner, J; Heinzel, G; Lehmann, H; Schneider, P; Trieb, G; von Nicolai, H, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adin, D | 1 |
| Kurtz, K | 1 |
| Atkins, C | 1 |
| Papich, MG | 1 |
| Vaden, S | 1 |
| Pariaut, R | 1 |
| Jung, SW | 1 |
| Vila, J | 1 |
| Newhard, DK | 1 |
| Boswood, A | 2 |
| Gordon, SG | 1 |
| Häggström, J | 1 |
| Wess, G | 1 |
| Stepien, RL | 1 |
| Oyama, MA | 2 |
| Keene, BW | 1 |
| Bonagura, J | 1 |
| MacDonald, KA | 1 |
| Patteson, M | 1 |
| Smith, S | 1 |
| Fox, PR | 1 |
| Sanderson, K | 1 |
| Woolley, R | 1 |
| Szatmári, V | 1 |
| Menaut, P | 1 |
| Church, WM | 1 |
| O'Sullivan, ML | 1 |
| Jaudon, JP | 1 |
| Kresken, JG | 1 |
| Rush, J | 1 |
| Barrett, KA | 1 |
| Rosenthal, SL | 1 |
| Saunders, AB | 1 |
| Ljungvall, I | 1 |
| Deinert, M | 1 |
| Bomassi, E | 1 |
| Estrada, AH | 1 |
| Fernandez Del Palacio, MJ | 1 |
| Moise, NS | 1 |
| Abbott, JA | 1 |
| Fujii, Y | 1 |
| Spier, A | 1 |
| Luethy, MW | 1 |
| Santilli, RA | 1 |
| Uechi, M | 1 |
| Tidholm, A | 1 |
| Schummer, C | 1 |
| Watson, P | 1 |
| Hillyer, S | 1 |
| Hezzell, M | 1 |
| Place, E | 1 |
| Schneider, P | 1 |
| Güttner, J | 1 |
| Eckenfels, A | 1 |
| Heinzel, G | 1 |
| von Nicolai, H | 1 |
| Trieb, G | 1 |
| Lehmann, H | 1 |
| Galatulas, I | 1 |
| Bossa, R | 1 |
| Efstathiu, G | 1 |
| Ninci, MA | 1 |
| Remme, WJ | 1 |
| Wiesfeld, AC | 1 |
| Look, MP | 1 |
| Kruyssen, HA | 1 |
2 reviews available for pimobendan and Cardiac Diseases
| Article | Year |
|---|---|
Is treatment with pimobendan associated with an increased risk of arrhythmias in dogs with heart disease?
Topics: Animals; Arrhythmias, Cardiac; Dog Diseases; Dogs; Heart Diseases; Pyridazines; Vasodilator Agents | 2018 |
Current use of pimobendan in canine patients with heart disease.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Diseases; Ma | 2010 |
1 trial available for pimobendan and Cardiac Diseases
| Article | Year |
|---|---|
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Heart Diseases; Hea | 2018 |
7 other studies available for pimobendan and Cardiac Diseases
| Article | Year |
|---|---|
Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Dog Diseases; Dogs; Electrolytes; Hear | 2020 |
Resolution of caval syndrome during initial hemodynamic stabilization in dogs with heartworm disease.
Topics: Animals; Cardiotonic Agents; Dirofilariasis; Dog Diseases; Dogs; Female; Heart Diseases; Hemodynamic | 2020 |
Clarification.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Heart Diseases; Pyridazines | 2018 |
Canine heart disease: progress and promise.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Dog Diseases; Dogs; Forecasti | 2008 |
Comparative cardiac toxicity of the i.v. administered benzimidazole pyridazinon derivative Pimobendan and its enantiomers in female Beagle dogs.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Dogs; Female; Heart Diseases; Heart Rate; Heart Valves; | 1997 |
Esorubicin cardiotoxicity in vitro: antagonism by pimobendan.
Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Electric Stimulation; Guin | 1990 |
Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction.
Topics: Aged; Cardiotonic Agents; Heart Diseases; Heart Ventricles; Hemodynamics; Humans; Injections, Intrav | 1989 |